SCHEMBL22194397

SCHEMBL22194397

N#C[C@H]1[C@H]2CN(c3cccc(F)c3)C[C@@H]12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.46
FAAH O00519 1/20 0.41
MGLL Q99685 1/20 0.41
ALOX5 P09917 1/20 0.38
C1S P09871 3/20 0.37
FADS1 O60427 1/20 0.37
TRPA1 O75762 3/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
PIK3CD O00329 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
GRM2 Q14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22194398 1.00 BPTF (0.46) BPTFFAAHMGLLALOX5C1S
SCHEMBL22194396 1.00 BPTF (0.46) BPTFFAAHMGLLALOX5C1S
SCHEMBL29539890 1.00 BPTF (0.46) BPTFFAAHMGLLALOX5C1S
SCHEMBL29540520 1.00 BPTF (0.46) BPTFFAAHMGLLALOX5C1S
SCHEMBL22194636 0.81 HTR3E (0.46) MGLLMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL22209995 0.81 HTR3E (0.46) MGLLMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL22194632 0.81 HTR3E (0.46) MGLLMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL29540270 0.81 HTR3E (0.46) MGLLMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL22194638 0.81 HTR3E (0.46) MGLLMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL22209970 0.79 BPTF (0.46) BPTFMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 BPTF 4510/4885FAAH 656/4885MGLL 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.